Benitec Biopharma, Inc. (BNTC)
8.65
-0.17
(-1.93%)
USD |
NASDAQ |
Oct 23, 16:00
8.64
-0.01
(-0.12%)
After-Hours: 20:00
Benitec Biopharma Enterprise Value : 118.38M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 118.38M |
| October 22, 2026 | 124.23M |
| October 21, 2026 | 113.22M |
| October 20, 2026 | 131.80M |
| October 19, 2026 | 108.40M |
| October 16, 2026 | 99.80M |
| October 15, 2026 | 111.84M |
| October 14, 2026 | 105.99M |
| October 13, 2026 | 117.69M |
| October 12, 2026 | 132.84M |
| October 09, 2026 | 125.95M |
| October 08, 2026 | 121.82M |
| October 07, 2026 | 130.08M |
| October 06, 2026 | 130.43M |
| October 05, 2026 | 138.34M |
| October 02, 2026 | 129.74M |
| October 01, 2026 | 150.39M |
| September 30, 2026 | 164.84M |
| September 29, 2026 | 156.24M |
| September 28, 2026 | 165.53M |
| September 25, 2026 | 150.73M |
| September 24, 2026 | 152.45M |
| September 23, 2026 | 158.99M |
| September 22, 2026 | 197.54M |
| September 21, 2026 | 195.13M |
| Date | Value |
|---|---|
| September 18, 2026 | 199.95M |
| September 17, 2026 | 211.65M |
| September 16, 2026 | 200.64M |
| September 15, 2026 | 200.98M |
| September 14, 2026 | 236.43M |
| September 11, 2026 | 240.22M |
| September 10, 2026 | 241.25M |
| September 09, 2026 | 249.17M |
| September 08, 2026 | 258.63M |
| September 04, 2026 | 257.08M |
| September 03, 2026 | 248.82M |
| September 02, 2026 | 263.96M |
| September 01, 2026 | 244.35M |
| August 31, 2026 | 239.53M |
| August 28, 2026 | 249.85M |
| August 27, 2026 | 256.74M |
| August 26, 2026 | 263.96M |
| August 25, 2026 | 268.78M |
| August 24, 2026 | 258.11M |
| August 21, 2026 | 284.61M |
| August 20, 2026 | 268.44M |
| August 19, 2026 | 281.17M |
| August 18, 2026 | 263.96M |
| August 17, 2026 | 270.50M |
| August 14, 2026 | 252.95M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.514B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| Anika Therapeutics, Inc. | 273.50M |
| Savara, Inc. | 724.16M |
| Vericel Corp. | 2.108B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -12.81M |
| Total Expenses (Quarterly) | 12.81M |
| EPS Diluted (Quarterly) | -0.3722 |
| Earnings Yield | -12.57% |
| Normalized Earnings Yield | -12.57 |